Rahim Shafa MD

PubMed

• 28 citations
  Aberrant transcriptomes and DNA methylomes define pathways that drive pathogenesis and loss of brain laterality/asymmetry in schizophrenia and bipolar disorder.
  Hamid Mostafavi Abdolmaleky, Adam C. Gower, Chen‐Khuan Wong, Jiayi Wu Cox, Xiaoling Zhang
  American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics. 2019-03-01
• 73 citations
  DNA hypermethylation of serotonin transporter gene promoter in drug naïve patients with schizophrenia
  Hamid Mostafavi Abdolmaleky, Shabnam Nohesara, Mohammad Ghadirivasfi, Arthur W. Lambert, Hamid Reza Ahmadkhaniha
  Schizophrenia Research. 2014-02-01
• 321 citations
  Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder
  Hamid Mostafavi Abdolmaleky, Kuang-hung Cheng, Stephen V. Faraone, Marsha A. Wilcox, Stephen J. Glatt
  Human Molecular Genetics. 2006-11-01

Abstracts/Posters

• “COMT-Inhibitors May Improve Long Term Buprenorphine Treatment Adherence”. Poster
  Shafa R, Abdolmaleky HM, Eskandari MR, Cano S, American Academy of Addiction Psychiatry Annual Meeting, Scottsdale, AZ, 12/1/2013
• “Utilizing (Catechol – O – Methyltransferase) COMT-Inhibition Effect in Detoxification off Buprenorphine, Methadone and other Opiates (an Opiate Addiction Anti-Craving...
  Shafa R, Abdolmaleky HM, Eskandari MR, Yaqubi S, Ghaemi SN, American Academy of Addiction Psychiatry Annual Meeting, Miami, FL, 12/1/2012
• “Inhibition of COMT (Catechol-O-Methyl-Transferase) Activity, As an Innovative Approach in Pharmacotherapy of Alcohol”.
  Shafa R, Abdolmaleky HM, Eskandari MR, Yaqubi S, Ghaemi SN, American Journal on Addictions, 7/1/2012
• “Inhibition of COMT (Catechol-O-Methyl-Transferase) Activity, As an Innovative Approach in Pharmacotherapy of Alcohol”. Poster
  Shafa R, Abdolmaleky HM, Eskandari MR, Yaqubi S, Ghaemi SN, American Academy of Addiction Psychiatry Annual Meeting, Scottsdale, AZ, 12/1/2011
• “Modulation of Dopamine Pathways Via COMT- Inhibitors May Provide an Alternative Strategy in Smoke Cessation (Pilot)”.
  Shafa R, Abdolmaleky HM, Eskandari MR, Yaqubi S, Ghaemi SN, American Journal on Addictions, 7/1/2011
• "Modulation of Dopamine Pathways Via COMT- Inhibitors May Provide an Alternative Strategy in Smoke Cessation (Pilot)”. Poster
  Shafa R, Abdolmaleky HM, Eskandari MR, Yaqubi S, Ghaemi SN, American Academy of Addiction Psychiatry Annual Meeting, Boca Raton, FL, 12/1/2010
• “COMT Inhibition May Offer a New Hope in Treatment of Cocaine Craving (Pilot)”.
  Shafa R, Abdolmaleky HM, Yaqubi S, Ghaemi SN, American Journal on Addictions, 7/1/2010
• “COMT Inhibition May Offer a New Hope in Treatment of Cocaine Craving (Pilot)”. Poster
  Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Ghaemi SN, American Academy of Addiction Psychiatry Annual Meeting, Los Angeles, CA, 12/1/2009
• “COMT-inhibitors may be a promising tool in treatment of Marijuana Addiction.”
  Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Ghaemi SN, American Journal on Addictions, 7/1/2009
• “COMT-Inhibitors May be a Promising Tool in Treatment of Marijuana Addiction”. Poster
  Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Ghaemi SN, American Academy of Addiction Psychiatry Annual Meeting, Boca Raton, FL, 12/1/2008
• “Entacapone as a novel anti-craving treatment in Substance abuse and Dependence.”
  Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Ghaemi SN, American Journal of Addiction, 7/1/2008
• “Entacapone (COMTAN)® in treatment of bipolar depression in patients with or without co-morbidity of substance abuse.”
  Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Koziol R, Ghaemi SN, 7/1/2008
• “Entacapone (COMTAN)® in treatment of bipolar depression in patients with or without co-morbidity of substance abuse.” Poster
  Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Koziol R, Ghaemi SN, Munich, Germany, 7/1/2008
• “A Successful Trial of Cathecol-O-Methyltransferase (COMT) Inhibitor Agent (Entacapone) in Treatment of Negative and Positive Symptoms of Schizophrenia. (A Pilot Stud...
  Shafa R, Abdolmaleky HM, Yaqubi S, Smith CL, Tsuang M, Ghaemi SN, APA New Research Abstracts, 5/1/2008
• “A Successful Trial of Cathecol-O-Methyltransferase (COMT) Inhibitor Agent (Entacapone) in Treatment of Negative and Positive Symptoms of Schizophrenia. (A Pilot Study...
  Shafa R, Abdolmaleky HM, Yagubi S, Smith CL, Tsuang M, Ghaemi SN, American Psychiatric Association Annual Meeting, Washington, DC, 5/1/2008
• “Hyeractivity of MB-COMT in Schizophrenia and Bipolar Disorder: Genetic, Epigenetic and Translational Studies.” Poster
  Smith CL, Abdolmaleky HM, Shafa R, 16th European Congress of Psychiatry, Nice, France, 4/1/2008
• “Schizophrenia is linked to multiple Fragile Sites”. Poster
  Smith CL, Abdolmaleky HM, Shafa R, Schizophrenia Winter Workshop, Switzerland, 1/1/2008
• “Entacapone as a novel anti-craving treatment in Substance abuse and Dependance.” Poster
  Shafa R, Abdolmaleky HM, Yaqubi S, Ghaemi SN, American Academy of Addiction Psychiatry, San Diego, CA, 11/1/2007
• “Entacapone in Treatment of Schizophrenia, Bipolar Disorder and Substance Dependance.” Poster
  Shafa R, Abdolmaleky HM, Yaqubi S, Ghaemi SN, World Congress of Psychiatric Genetics XV, New York City, NY, 10/1/2007
• “Epigenetic and Genetic Modulation of Cathechol-O-Methyltransferase (COMT) in Brain Influences Risk for Schizophrenia and Bipolar Disoder.” Poster
  Abdolmaleky HM, Gae F, Chang KH, Faraone S, Wilcox M, Smith CL, Glatt S, Shafa R, Aleali B, Sivaraman V, Tsuang M, Thiagalingam S, Harvard Research Day, Boston, MA, 1/1/2006
• “Clozapine enhances P300 amplitude in patients with schizophrenia”.
  Patel, JK. Niznikiewicz, MA. Shafa, R. Singh, J. Canuso, C. McCarley, RW. Green, AI., 39th Annual Meeting of American College of Neuropsychopharmacology (ACNP), San Juan, Puerto Rico, 12/10/2000
• "Re-challenge with Clozapine: Cardiovascular Symptoms". Poster
  Shafa R, Patel JK, Kalinowski AG, Green AI, American Psychiatric Association, Annual Meeting, 5/1/1997
• "Brain Imaging and Positive Symtpoms During a First Episode of Schizophrenia". Poster
  Shafa R, Powsner R, Fischman AJ, Verma S, Harvard Research Day, 3/1/1997
• "Effect of Clozapine on Cognitive Functions in Treatment-Refractory Schizophrenia". Poster
  Stone WS, Seidman LJ, Kalinowski AG, Shagrin B, Patel JK, Shafa R, Canuso C, Schildkraut JJ, Green AI, V International Congress on Schizophrenia Research, 1/1/1997
• “Recruitment for Psychopharmacological Studies in Schizophrenia : Gender Differences”. Poster
  Dooley P, Patel JK, Kalinowski AG, Shafa R, Canuso C, Green AI, American Psychiatric Association Annual Meeting, 5/1/1996
• Join now to see all

Lectures

• Industry Sponsored Lectures, to medical & Psychiatric communities, topics specified to Novel Antipsychotics, Anticonvulsants, Wake Promoting Agents and Laboratory Toxi... 
  Diverse venues throughout MA. RI. & CT (2002-present) - 1/1/2014
• Workshop “Cannabis Dependence in Adolescents: Approach to Frequently Asked Questions on Vulnerability, Assessment, and Management” 
  Honolulu, HI - 10/27/2009
• Workshop “Everything you Wanted to Know about Adolescents and Cannabis" 
  Boca Raton, FL - 12/4/2008
• Grand Round, “COMT-Inhibition as a Novel Anti-Craving Modality in Substance Abuse & Dependence" 
  University of Mass. Westborough State Hospital, Westborough, MA - 2/5/2008
• Join now to see all

Other

• Review Article: “Gentics And Genomics, Psychitric Epigenetics, A Key to the Molecular Basis of and Therapy for Psychiatric Disorders.” 
  Hamid M. Abdolmaleky, Rahim Shafa, Ming T. Tsuang, Sam Thiangalingam, Psychiatric Times, A UBM Medica Publication
  http://www.PsychiatricTimes.com
  6/1/2013
• Dissertation: "Hysteria (Dissociative and Conversion Disorders) an Overview of Etiology, Clinical Manifestations and Treatment, 1982”. 
  Shafa R, National University of Iran Medical Library
  1/1/1982
• “Platonic Love: A Discussion of the Implications of Platonic Love on One’s Mental Health”. 
  Shafa R, University Press (National University of Iran Medical Library)
  Tehran, Iran - 1/1/1977